Scolaris Content Display Scolaris Content Display

Antagonistas de la vitamina K versus heparina de bajo peso molecular para el tratamiento a largo plazo de la tromboembolia venosa sintomática

Appendices

Appendix 1. CENTRAL search strategy

#1

MESH DESCRIPTOR Thrombosis

1234

#2

MESH DESCRIPTOR Thromboembolism

896

#3

MESH DESCRIPTOR Venous Thromboembolism

239

#4

MESH DESCRIPTOR Venous Thrombosis EXPLODE ALL TREES

2001

#5

(thromboprophyla* or thrombus* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or embol*):TI,AB,KY

17573

#6

MESH DESCRIPTOR Pulmonary Embolism EXPLODE ALL TREES

734

#7

(PE or DVT or VTE):TI,AB,KY

4603

#8

(((vein* or ven*) near thromb*)):TI,AB,KY

6271

#9

#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8

20979

#10

MESH DESCRIPTOR Anticoagulants

3271

#11

MESH DESCRIPTOR Coumarins EXPLODE ALL TREES

1618

#12

(((vitamin k or vit k) near3 antagon*)):TI,AB,KY

370

#13

VKA:TI,AB,KY

140

#14

anticoagula*:TI,AB,KY

7493

#15

anti‐coagula*:TI,AB,KY

146

#16

warfarin*:TI,AB,KY

2809

#17

*coum* :TI,AB,KY

834

#18

(Jantoven or Marevan or Lawarin or Waran or Warfant or Dindevan):TI,AB,KY

4

#19

phenindione:TI,AB,KY

33

#20

(Sinthrome or Sintrom):TI,AB,KY

8

#21

(Marcumar or Falithrom):TI,AB,KY

10

#22

(aldocumar or tedicumar):TI,AB,KY

0

#23

#10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22

9306

#24

MESH DESCRIPTOR Heparin, Low‐Molecular‐Weight EXPLODE ALL TREES

1488

#25

(low near4 hepar* ):TI,AB,KY

3132

#26

(LMWH or LMH):TI,AB,KY

802

#27

(nadroparin* or fraxiparin* or enoxaparin):TI,AB,KY

1620

#28

(Clexane or klexane or lovenox):TI,AB,KY

42

#29

(dalteparin or Fragmin or ardeparin):TI,AB,KY

561

#30

(normiflo or tinzaparin or logiparin):TI,AB,KY

182

#31

(Innohep or certoparin or sandoparin or reviparin):TI,AB,KY

134

#32

(clivarin* or danaproid or danaparoid):TI,AB,KY

56

#33

(antixarin or ardeparin* or bemiparin*):TI,AB,KY

42

#34

(Zibor or cy 222 or embolex or monoembolex):TI,AB,KY

38

#35

(parnaparin* or rd 11885 or RD1185):TI,AB,KY

27

#36

(tedelparin or Kabi‐2165 or Kabi 2165):TI,AB,KY

42

#37

(emt‐966 or emt‐967 or pk‐10 169 or pk‐10169 or pk10169):TI,AB,KY

8

#38

(fr‐860 or cy‐216 or cy216):TI,AB,KY

51

#39

(seleparin* or tedegliparin or seleparin* or tedegliparin*):TI,AB,KY

1

#40

("kb 101" or kb101 or lomoparan or orgaran):TI,AB,KY

31

#41

(parnaparin or fluxum or lohepa or lowhepa):TI,AB,KY

33

#42

(op 2123 or parvoparin):TI,AB,KY

1

#43

calciparin*:TI,AB,KY

22

#44

#24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42

4570

#45

#9 AND #23 AND #44

1187

#46

15/02/2012 TO 31/10/2016:DL

308891

#47

#45 AND #46

446

Appendix 2. Trials registries searches

ClinicalTrials.gov

44 studies found for: Thromboembolism OR thrombosis OR DVT in Condition AND

(vitamin k antagonist OR warfarin OR coumadin OR phenprocoumon OR acenocoumarol OR dicoumarol) AND heparin in Interventions

World Health Organization International Clinical Trials Registry Platform

496 records for 138 trials for: Thromboembolism OR thrombosis OR DVT in Condition AND

(warfarin OR coumadin OR phenprocoumon OR acenocoumarol OR dicoumarol) AND heparin in Intervention

ISRCTN Register

3 results found for (warfarin OR coumadin OR phenprocoumon OR acenocoumarol OR dicoumarol) AND (thromboembolism or thrombosis or DVT)

Appendix 3. Glossary

anticoagulant: medicine that helps prevent blood clots

intravenous: into the vein(s)

oral anticoagulant: anticoagulant taken by mouth

parenteral anticoagulant: administration of anticoagulant by injection or infusion

subcutaneous: under the skin

Study flow diagram.
Figuras y tablas -
Figure 1

Study flow diagram.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials.
Figuras y tablas -
Figure 2

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Risk of bias summary: review authors' judgements about each risk of bias item for each included trial.
Figuras y tablas -
Figure 3

Risk of bias summary: review authors' judgements about each risk of bias item for each included trial.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Funnel plot of comparison: 2 LMWH versus VKA during three months of allocated treatment (category I and II trials); outcome: 2.1 incidence of recurrent VTE.
Figuras y tablas -
Figure 4

Funnel plot of comparison: 2 LMWH versus VKA during three months of allocated treatment (category I and II trials); outcome: 2.1 incidence of recurrent VTE.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Funnel plot of comparison: 2 LMWH versus VKA during three months of allocated treatment (category I and II trials); outcome: 2.2 incidence of major bleeding.
Figuras y tablas -
Figure 5

Funnel plot of comparison: 2 LMWH versus VKA during three months of allocated treatment (category I and II trials); outcome: 2.2 incidence of major bleeding.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Funnel plot of comparison: 2 LMWH versus VKA during three months of allocated treatment (category I and II trials), outcome; 2.3 mortality.
Figuras y tablas -
Figure 6

Funnel plot of comparison: 2 LMWH versus VKA during three months of allocated treatment (category I and II trials), outcome; 2.3 mortality.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 LMWH versus VKA during allocated treatment (category I and II trials) in participants with VTE, Outcome 1 Incidence of recurrent VTE.
Figuras y tablas -
Analysis 1.1

Comparison 1 LMWH versus VKA during allocated treatment (category I and II trials) in participants with VTE, Outcome 1 Incidence of recurrent VTE.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 LMWH versus VKA during allocated treatment (category I and II trials) in participants with VTE, Outcome 2 Incidence of major bleeding.
Figuras y tablas -
Analysis 1.2

Comparison 1 LMWH versus VKA during allocated treatment (category I and II trials) in participants with VTE, Outcome 2 Incidence of major bleeding.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 LMWH versus VKA during allocated treatment (category I and II trials) in participants with VTE, Outcome 3 Mortality.
Figuras y tablas -
Analysis 1.3

Comparison 1 LMWH versus VKA during allocated treatment (category I and II trials) in participants with VTE, Outcome 3 Mortality.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 LMWH versus VKA during allocated treatment (category I and II trials) in participants with DVT, Outcome 1 Incidence of recurrent VTE.
Figuras y tablas -
Analysis 2.1

Comparison 2 LMWH versus VKA during allocated treatment (category I and II trials) in participants with DVT, Outcome 1 Incidence of recurrent VTE.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 LMWH versus VKA during allocated treatment (category I and II trials) in participants with DVT, Outcome 2 Incidence of major bleeding.
Figuras y tablas -
Analysis 2.2

Comparison 2 LMWH versus VKA during allocated treatment (category I and II trials) in participants with DVT, Outcome 2 Incidence of major bleeding.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 LMWH versus VKA during allocated treatment (category I and II trials) in participants with DVT, Outcome 3 Mortality.
Figuras y tablas -
Analysis 2.3

Comparison 2 LMWH versus VKA during allocated treatment (category I and II trials) in participants with DVT, Outcome 3 Mortality.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 LMWH versus VKA during allocated treatment (category I and II trials) in participants with PE, Outcome 1 Incidence of recurrent VTE.
Figuras y tablas -
Analysis 3.1

Comparison 3 LMWH versus VKA during allocated treatment (category I and II trials) in participants with PE, Outcome 1 Incidence of recurrent VTE.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 LMWH versus VKA during allocated treatment (category I and II trials) in participants with PE, Outcome 2 Incidence of major bleeding.
Figuras y tablas -
Analysis 3.2

Comparison 3 LMWH versus VKA during allocated treatment (category I and II trials) in participants with PE, Outcome 2 Incidence of major bleeding.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 LMWH versus VKA during allocated treatment (category I and II trials) in participants with PE, Outcome 3 Mortality.
Figuras y tablas -
Analysis 3.3

Comparison 3 LMWH versus VKA during allocated treatment (category I and II trials) in participants with PE, Outcome 3 Mortality.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 LMWH versus VKA during allocated treatment (category I trials) in participants with VTE, Outcome 1 Incidence of recurrent VTE.
Figuras y tablas -
Analysis 4.1

Comparison 4 LMWH versus VKA during allocated treatment (category I trials) in participants with VTE, Outcome 1 Incidence of recurrent VTE.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 LMWH versus VKA during allocated treatment (category I trials) in participants with VTE, Outcome 2 Incidence of major bleeding.
Figuras y tablas -
Analysis 4.2

Comparison 4 LMWH versus VKA during allocated treatment (category I trials) in participants with VTE, Outcome 2 Incidence of major bleeding.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 LMWH versus VKA during allocated treatment (category I trials) in participants with VTE, Outcome 3 Mortality.
Figuras y tablas -
Analysis 4.3

Comparison 4 LMWH versus VKA during allocated treatment (category I trials) in participants with VTE, Outcome 3 Mortality.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Category I trials and the same initial treatment in both groups (unfractionated heparin or LMWH), Outcome 1 Incidence of recurrent VTE.
Figuras y tablas -
Analysis 5.1

Comparison 5 Category I trials and the same initial treatment in both groups (unfractionated heparin or LMWH), Outcome 1 Incidence of recurrent VTE.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Category I trials and the same initial treatment in both groups (unfractionated heparin or LMWH), Outcome 2 Incidence of major bleeding.
Figuras y tablas -
Analysis 5.2

Comparison 5 Category I trials and the same initial treatment in both groups (unfractionated heparin or LMWH), Outcome 2 Incidence of major bleeding.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Category I trials and the same initial treatment in both groups (unfractionated heparin or LMWH), Outcome 3 Mortality.
Figuras y tablas -
Analysis 5.3

Comparison 5 Category I trials and the same initial treatment in both groups (unfractionated heparin or LMWH), Outcome 3 Mortality.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Category I trials and initial treatment not the same in both groups (unfractionated heparin compared with LMWH), Outcome 1 Incidence of recurrent VTE.
Figuras y tablas -
Analysis 6.1

Comparison 6 Category I trials and initial treatment not the same in both groups (unfractionated heparin compared with LMWH), Outcome 1 Incidence of recurrent VTE.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Category I trials and initial treatment not the same in both groups (unfractionated heparin compared with LMWH), Outcome 2 Incidence of major bleeding.
Figuras y tablas -
Analysis 6.2

Comparison 6 Category I trials and initial treatment not the same in both groups (unfractionated heparin compared with LMWH), Outcome 2 Incidence of major bleeding.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Category I trials and initial treatment not the same in both groups (unfractionated heparin compared with LMWH), Outcome 3 Mortality.
Figuras y tablas -
Analysis 6.3

Comparison 6 Category I trials and initial treatment not the same in both groups (unfractionated heparin compared with LMWH), Outcome 3 Mortality.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 LMWH versus VKA during additional follow‐up (category I and II trials), Outcome 1 Incidence of recurrent VTE.
Figuras y tablas -
Analysis 7.1

Comparison 7 LMWH versus VKA during additional follow‐up (category I and II trials), Outcome 1 Incidence of recurrent VTE.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 LMWH versus VKA during additional follow‐up (category I and II trials), Outcome 2 Incidence of major bleeding.
Figuras y tablas -
Analysis 7.2

Comparison 7 LMWH versus VKA during additional follow‐up (category I and II trials), Outcome 2 Incidence of major bleeding.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 LMWH versus VKA during additional follow‐up (category I and II trials), Outcome 3 Mortality.
Figuras y tablas -
Analysis 7.3

Comparison 7 LMWH versus VKA during additional follow‐up (category I and II trials), Outcome 3 Mortality.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 LMWH versus VKA during additional nine months of follow‐up (category I trials), Outcome 1 Incidence of recurrent VTE.
Figuras y tablas -
Analysis 8.1

Comparison 8 LMWH versus VKA during additional nine months of follow‐up (category I trials), Outcome 1 Incidence of recurrent VTE.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 LMWH versus VKA during additional nine months of follow‐up (category I trials), Outcome 2 Incidence of major bleeding.
Figuras y tablas -
Analysis 8.2

Comparison 8 LMWH versus VKA during additional nine months of follow‐up (category I trials), Outcome 2 Incidence of major bleeding.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 LMWH versus VKA during additional nine months of follow‐up (category I trials), Outcome 3 Mortality.
Figuras y tablas -
Analysis 8.3

Comparison 8 LMWH versus VKA during additional nine months of follow‐up (category I trials), Outcome 3 Mortality.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 LMWH versus VKA for total period of 12 months of follow‐up (category I and II trials), Outcome 1 Incidence of recurrent VTE.
Figuras y tablas -
Analysis 9.1

Comparison 9 LMWH versus VKA for total period of 12 months of follow‐up (category I and II trials), Outcome 1 Incidence of recurrent VTE.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 LMWH versus VKA for total period of 12 months of follow‐up (category I and II trials), Outcome 2 Incidence of major bleeding.
Figuras y tablas -
Analysis 9.2

Comparison 9 LMWH versus VKA for total period of 12 months of follow‐up (category I and II trials), Outcome 2 Incidence of major bleeding.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 LMWH versus VKA for total period of 12 months of follow‐up (category I and II trials), Outcome 3 Mortality.
Figuras y tablas -
Analysis 9.3

Comparison 9 LMWH versus VKA for total period of 12 months of follow‐up (category I and II trials), Outcome 3 Mortality.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 LMWH versus VKA for total period of 12 months of follow‐up (category I trials), Outcome 1 Incidence of recurrent VTE.
Figuras y tablas -
Analysis 10.1

Comparison 10 LMWH versus VKA for total period of 12 months of follow‐up (category I trials), Outcome 1 Incidence of recurrent VTE.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 LMWH versus VKA for total period of 12 months of follow‐up (category I trials), Outcome 2 Incidence of major bleeding.
Figuras y tablas -
Analysis 10.2

Comparison 10 LMWH versus VKA for total period of 12 months of follow‐up (category I trials), Outcome 2 Incidence of major bleeding.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 LMWH versus VKA for total period of 12 months of follow‐up (category I trials), Outcome 3 Mortality.
Figuras y tablas -
Analysis 10.3

Comparison 10 LMWH versus VKA for total period of 12 months of follow‐up (category I trials), Outcome 3 Mortality.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Summary of findings for the main comparison. LMWH compared with VKA for long term treatment of symptomatic VTE

LMWH compared with VKA for long term treatment of symptomatic VTE

Patient or population: patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE
Setting: hospital and outpatient
Intervention: LMWH
Comparison: VKA

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

Number of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with VKA

Risk with LMWH

Incidence of recurrent VTE

(treatment duration 3 months)

Study population

Peto OR 0.83
(0.60 to 1.15)

3299
(16 RCTs)

⊕⊕⊕⊝
MODERATEa,b

51 per 1000

42 per 1000
(31 to 58)

Incidence of major bleeding

(treatment duration 3 months)

Study population

Peto OR 0.51
(0.32 to 0.80)

3299
(16 RCTs)

⊕⊕⊝⊝
LOWc,d

29 per 1000

15 per 1000
(10 to 24)

Mortality

(treatment duration 3 months)

Study population

Peto OR 1.08
(0.75 to 1.56)

3299
(16 RCTs)

⊕⊕⊕⊝
MODERATEa,b

35 per 1000

37 per 1000
(26 to 53)

* The basis for the assumed risk with VKA for 'Study population' was the average risk in the VKA group (i.e. total number of participants with events divided by total number of participants in the VKA group included in the meta‐analysis). The risk in the LMWH group (and its 95% confidence interval) is based on assumed risk in the VKA group and the relative effect of the intervention (and its 95% CI)

CI: confidence interval; LMWH: low‐molecular‐weight heparin; OR: odds ratio; VKA: vitamin K antagonist; VTE: venous thromboembolism

GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

aHigh risk of bias due to no blinding but not downgraded, as analysis excluding studies deemed of low methodological quality confirms no clear differences between LMWH and VKA
bDowngraded by one level owing to imprecision, small number of events, and relatively large confidence interval
cDowngraded by one level for risk of bias, as sensitivity analysis based on category I trials (clearly concealed randomisation, double‐blind or blinded outcome assessment) shows no clear differences between VKA and LMWH. Bleeding outcomes are more susceptible to biased outcome reporting than outcomes such as VTE and mortality
dDowngraded by one level for inconsistency: only two studies (studies of low methodological quality) reported less bleeding for LMWH, and the remainder showed no clear differences, with confidence intervals crossing the line of no effect

Figuras y tablas -
Summary of findings for the main comparison. LMWH compared with VKA for long term treatment of symptomatic VTE
Ir a la tabla de la revisión
Comparison 1. LMWH versus VKA during allocated treatment (category I and II trials) in participants with VTE

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Incidence of recurrent VTE Show forest plot

16

3299

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.83 [0.60, 1.15]

2 Incidence of major bleeding Show forest plot

16

3299

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.51 [0.32, 0.80]

3 Mortality Show forest plot

16

3299

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.08 [0.75, 1.56]
Figuras y tablas -
Comparison 1. LMWH versus VKA during allocated treatment (category I and II trials) in participants with VTE
Ir a la tabla de la revisión
Comparison 2. LMWH versus VKA during allocated treatment (category I and II trials) in participants with DVT

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Incidence of recurrent VTE Show forest plot

12

3021

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.79 [0.57, 1.11]

2 Incidence of major bleeding Show forest plot

12

3021

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.54 [0.33, 0.88]

3 Mortality Show forest plot

12

3021

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.10 [0.75, 1.60]
Figuras y tablas -
Comparison 2. LMWH versus VKA during allocated treatment (category I and II trials) in participants with DVT
Ir a la tabla de la revisión
Comparison 3. LMWH versus VKA during allocated treatment (category I and II trials) in participants with PE

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Incidence of recurrent VTE Show forest plot

3

202

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.70 [0.91, 35.60]

2 Incidence of major bleeding Show forest plot

3

202

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.23 [0.03, 1.78]

3 Mortality Show forest plot

3

202

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.39 [0.51, 57.36]
Figuras y tablas -
Comparison 3. LMWH versus VKA during allocated treatment (category I and II trials) in participants with PE
Ir a la tabla de la revisión
Comparison 4. LMWH versus VKA during allocated treatment (category I trials) in participants with VTE

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Incidence of recurrent VTE Show forest plot

7

1872

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.80 [0.54, 1.18]

2 Incidence of major bleeding Show forest plot

7

1872

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.62 [0.36, 1.07]

3 Mortality Show forest plot

7

1872

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.92 [0.61, 1.41]
Figuras y tablas -
Comparison 4. LMWH versus VKA during allocated treatment (category I trials) in participants with VTE
Ir a la tabla de la revisión
Comparison 5. Category I trials and the same initial treatment in both groups (unfractionated heparin or LMWH)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Incidence of recurrent VTE Show forest plot

2

292

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.95 [0.74, 5.19]

2 Incidence of major bleeding Show forest plot

2

292

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.01 [0.20, 5.12]

3 Mortality Show forest plot

2

292

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.89 [0.29, 2.68]
Figuras y tablas -
Comparison 5. Category I trials and the same initial treatment in both groups (unfractionated heparin or LMWH)
Ir a la tabla de la revisión
Comparison 6. Category I trials and initial treatment not the same in both groups (unfractionated heparin compared with LMWH)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Incidence of recurrent VTE Show forest plot

5

1580

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.68 [0.44, 1.03]

2 Incidence of major bleeding Show forest plot

5

1580

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.59 [0.33, 1.04]

3 Mortality Show forest plot

5

1580

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.93 [0.59, 1.46]
Figuras y tablas -
Comparison 6. Category I trials and initial treatment not the same in both groups (unfractionated heparin compared with LMWH)
Ir a la tabla de la revisión
Comparison 7. LMWH versus VKA during additional follow‐up (category I and II trials)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Incidence of recurrent VTE Show forest plot

10

2592

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.12 [0.77, 1.64]

2 Incidence of major bleeding Show forest plot

9

2112

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

3 Mortality Show forest plot

10

2592

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.00 [0.71, 1.40]
Figuras y tablas -
Comparison 7. LMWH versus VKA during additional follow‐up (category I and II trials)
Ir a la tabla de la revisión
Comparison 8. LMWH versus VKA during additional nine months of follow‐up (category I trials)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Incidence of recurrent VTE Show forest plot

5

1691

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.26 [0.81, 1.98]

2 Incidence of major bleeding Show forest plot

4

1211

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

3 Mortality Show forest plot

5

1691

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.06 [0.72, 1.55]
Figuras y tablas -
Comparison 8. LMWH versus VKA during additional nine months of follow‐up (category I trials)
Ir a la tabla de la revisión
Comparison 9. LMWH versus VKA for total period of 12 months of follow‐up (category I and II trials)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Incidence of recurrent VTE Show forest plot

10

2592

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.88 [0.67, 1.15]

2 Incidence of major bleeding Show forest plot

9

2112

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.56 [0.33, 0.95]

3 Mortality Show forest plot

10

2592

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.09 [0.84, 1.43]
Figuras y tablas -
Comparison 9. LMWH versus VKA for total period of 12 months of follow‐up (category I and II trials)
Ir a la tabla de la revisión
Comparison 10. LMWH versus VKA for total period of 12 months of follow‐up (category I trials)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Incidence of recurrent VTE Show forest plot

5

1691

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.95 [0.70, 1.30]

2 Incidence of major bleeding Show forest plot

4

1211

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.72 [0.39, 1.32]

3 Mortality Show forest plot

5

1691

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.05 [0.78, 1.42]
Figuras y tablas -
Comparison 10. LMWH versus VKA for total period of 12 months of follow‐up (category I trials)
Ir a la tabla de la revisión